NEOSE RECEIVES MILESTONE PAYMENT FROM NOVO NORDISK ON SECOND PROTEIN

A A

Neose Technologies, Inc. (Nasdaq: NTEC) today announced that it received a milestone payment from Novo Nordisk A/S (NYSE: NVO) under the license agreements entered into in November 2003 to use Neose's GlycoPEGylation(TM) technology to develop next-generation versions of three currently-marketed therapeutic proteins. This is the second of the three proteins Novo is developing using the Neose technology for which a milestone payment has been received.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/11-21-2005/0004220825&EDATE=)